Carmeseal-HF (poloxamer 188 NF intravenous) / Phrixus Pharma - LARVOL DELTA

Safety and Efficacy of P-188 NF in DMD Patients (clinicaltrials.gov) - P2; N=10; Suspended; Sponsor: Phrixus Pharmaceuticals, Inc.; Trial completion date: Nov 2019 ➔ Nov 2020; Recruiting ➔ Suspended; Trial primary completion date: Sep 2019 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date • Trial suspension